Min Zhang1, C D'Arcy J Holman. 1. School of Population Health, The University of Western Australia, Perth, Western Australia, Australia. min.zhang@uwa.edu.au
Abstract
AIM: The aim of the present study was to investigate associations between ovarian cancer survival and reproductive, gynecological and hormone factors. MATERIAL AND METHODS: A prospective follow-up study was conducted in the Southeast of China. The cohort comprised 202 patients with histopathologically confirmed epithelial ovarian cancer who were enrolled during 1999-2000 and followed-up for 5years subsequently. One hundred and ninety five (96.5%) of the cohort or their close relatives were traced. Information was obtained on reproductive, gynecological and hormone factors prior to diagnosis, actual survival time and number of deaths. Cox proportional models were used to estimate mortality hazard ratios (HR) and associated 95% confidence intervals (CI) for tubal ligation, adjusting for age at diagnosis, body mass index (BMI), menopausal status, International Federation of Gynaecology and Obstetrics (FIGO) stage, histological grade of differentiation, cytology of ascites, and chemotherapy status. RESULTS: The HR was significantly increased and survival was worse in ovarian cancer patients with a previous tubal ligation, but not with any other reproductive, gynecological and hormone factor. Only 21 (38.9%) of 54 patients who had tubal ligation survived to the time of interview, in contrast to 95 women (67.4%) still alive among the 141 women without tubal ligation (P<0.001). Compared to the patients who had no tubal ligation, the adjusted HR was 1.62 (95% CI 1.01-2.59; P=0.04) for those who had tubal ligation. There was no association with age at menarche, menopausal status, parity, breastfeeding, hormone replacement therapy, oral contraceptive use, and hysterectomy. CONCLUSION: Previous tubal ligation was an independently adverse prognostic factor for epithelial ovarian cancer survival. Further studies that examine the relationship are warranted to confirm these results.
AIM: The aim of the present study was to investigate associations between ovarian cancer survival and reproductive, gynecological and hormone factors. MATERIAL AND METHODS: A prospective follow-up study was conducted in the Southeast of China. The cohort comprised 202 patients with histopathologically confirmed epithelial ovarian cancer who were enrolled during 1999-2000 and followed-up for 5years subsequently. One hundred and ninety five (96.5%) of the cohort or their close relatives were traced. Information was obtained on reproductive, gynecological and hormone factors prior to diagnosis, actual survival time and number of deaths. Cox proportional models were used to estimate mortality hazard ratios (HR) and associated 95% confidence intervals (CI) for tubal ligation, adjusting for age at diagnosis, body mass index (BMI), menopausal status, International Federation of Gynaecology and Obstetrics (FIGO) stage, histological grade of differentiation, cytology of ascites, and chemotherapy status. RESULTS: The HR was significantly increased and survival was worse in ovarian cancerpatients with a previous tubal ligation, but not with any other reproductive, gynecological and hormone factor. Only 21 (38.9%) of 54 patients who had tubal ligation survived to the time of interview, in contrast to 95 women (67.4%) still alive among the 141 women without tubal ligation (P<0.001). Compared to the patients who had no tubal ligation, the adjusted HR was 1.62 (95% CI 1.01-2.59; P=0.04) for those who had tubal ligation. There was no association with age at menarche, menopausal status, parity, breastfeeding, hormone replacement therapy, oral contraceptive use, and hysterectomy. CONCLUSION: Previous tubal ligation was an independently adverse prognostic factor for epithelial ovarian cancer survival. Further studies that examine the relationship are warranted to confirm these results.
Authors: Katharine K Brieger; Siri Peterson; Alice W Lee; Bhramar Mukherjee; Kelly M Bakulski; Aliya Alimujiang; Hoda Anton-Culver; Michael S Anglesio; Elisa V Bandera; Andrew Berchuck; David D L Bowtell; Georgia Chenevix-Trench; Kathleen R Cho; Daniel W Cramer; Anna DeFazio; Jennifer A Doherty; Renée T Fortner; Dale W Garsed; Simon A Gayther; Aleksandra Gentry-Maharaj; Ellen L Goode; Marc T Goodman; Holly R Harris; Estrid Høgdall; David G Huntsman; Hui Shen; Allan Jensen; Sharon E Johnatty; Susan J Jordan; Susanne K Kjaer; Jolanta Kupryjanczyk; Diether Lambrechts; Karen McLean; Usha Menon; Francesmary Modugno; Kirsten Moysich; Roberta Ness; Susan J Ramus; Jean Richardson; Harvey Risch; Mary Anne Rossing; Britton Trabert; Nicolas Wentzensen; Argyrios Ziogas; Kathryn L Terry; Anna H Wu; Gillian E Hanley; Paul Pharoah; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce Journal: Gynecol Oncol Date: 2020-07-06 Impact factor: 5.482
Authors: Elizabeth M Poole; Melissa A Merritt; Susan J Jordan; Hannah P Yang; Susan E Hankinson; Yikung Park; Bernard Rosner; Penelope M Webb; Daniel W Cramer; Nicolas Wentzensen; Kathryn L Terry; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-01-10 Impact factor: 4.254
Authors: Amy L Shafrir; Ana Babic; Rulla M Tamimi; Bernard A Rosner; Shelley S Tworoger; Kathryn L Terry Journal: Br J Cancer Date: 2016-10-04 Impact factor: 7.640
Authors: Jelena Bešević; Marc J Gunter; Renée T Fortner; Konstantinos K Tsilidis; Elisabete Weiderpass; N Charlotte Onland-Moret; Laure Dossus; Anne Tjønneland; Louise Hansen; Kim Overvad; Sylvie Mesrine; Laura Baglietto; Françoise Clavel-Chapelon; Rudolf Kaaks; Krasimira Aleksandrova; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Christina Bamia; Giovanna Masala; Claudia Agnoli; Rosario Tumino; Fulvio Ricceri; Salvatore Panico; H Bas Bueno-de-Mesquita; Petra H Peeters; Mie Jareid; J Ramón Quirós; Eric J Duell; María-José Sánchez; Nerea Larrañaga; María-Dolores Chirlaque; Aurelio Barricarte; Joana A Dias; Emily Sonestedt; Annika Idahl; Eva Lundin; Nicholas J Wareham; Kay-Tee Khaw; Ruth C Travis; Sabina Rinaldi; Isabelle Romieu; Elio Riboli; Melissa A Merritt Journal: Br J Cancer Date: 2015-11-10 Impact factor: 7.640